Episode

3D-Bioprinting: Gewebeimplantate aus dem Drucker – Alexander Leutner (Cellbricks Therapeutics)

Podcast: Startup Insider
Published: Apr 29, 2026
Duration seconds: 1964
Processing state: processed
Canonical source: https://startup-insider.com/alle-podcast-folgen/
Audio: https://afp-912057-injected.calisto.simplecastaudio.com/d2790bdf-c937-4878-8f59-941f6b6b4ef5/episodes/fa45544e-fe04-41c7-b524-6739ba00fcd0/audio/128/default.mp3?aid=rss_feed&awCollectionId=d2790bdf-c937-4878-8f59-941f6b6b4ef5&awEpisodeId=fa45544e-fe04-41c7-b524-6739ba00fcd0&feed=ZQdsoEnZ
JSON: /v1/public/podcasts/startup-insider-6744721/episodes/3d-bioprinting-gewebeimplantate-aus-dem-drucker-alexander-leutner-cellbricks-therapeutics
Markdown: /podcast/startup-insider-6744721/3d-bioprinting-gewebeimplantate-aus-dem-drucker-alexander-leutner-cellbricks-therapeutics.md

Actions

POST https://stenobird.com/v1/public/podcasts/startup-insider-6744721/episodes/3d-bioprinting-gewebeimplantate-aus-dem-drucker-alexander-leutner-cellbricks-therapeutics/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/startup-insider-6744721/3d-bioprinting-gewebeimplantate-aus-dem-drucker-alexander-leutner-cellbricks-therapeutics.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Cellbricks Therapeutics is developing a 3D-bioprinting platform to manufacture functional human tissue implants. The company aims to progress from wound healing applications to complex organ replacement through strategic pharmaceutical partnerships.

Topics

3D-Bioprinting
Regenerative Medicine
Deep Tech
Biotechnology
Tissue Engineering
Pharmaceutical Partnerships
Medical Innovation
Berlin Startups

Highlights

Main idea: Cellbricks utilizes a light-based bioprinting process to stabilize cells within a hydrogel structure
Practical takeaway: The platform model allows for scalable applications ranging from wound healing to breast reconstruction and organ replacement
Business model: The company pursues co-development deals with large pharma to leverage massive upfront and milestone payments
Failure mode: High R&D costs and the intense regulatory requirements of the biotech sector necessitate significant capital and strategic partnerships
Strategic vision: Using a platform approach enables the company to launch multiple assets and diversify therapeutic use cases

Chapters

1:00 Introduction to Cellbricks: An introduction to Alexander Leutner and the moonshot vision of biofabricated human tissue implants.
3:40 The Roadmap to Organ Replacement: Discussing the transition from simpler tissue manufacturing to the ultimate goal of complex organ replacement.
8:50 The Bioprinting Process: Technical details on using light to cure functionalized biomaterials into a cell-embedded hydrogel.
16:50 Platform Assets and Use Cases: How the technology scales from wound healing to advanced tissue reconstruction and dual-use defense applications.
19:20 The Pharma Partnership Model: Analyzing the economics of co-development deals, milestone payments, and the symbiosis between startups and Big Pharma.
22:00 Scaling and Fundraising: Insights into managing growth, securing venture capital, and navigating the deep-tech funding landscape in Germany.
32:30 Impact and Future Outlook: The broader implications of bioprinting for the deep-tech ecosystem, investors, and the global medical community.